The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST

Abstract

The objective response is an important endpoint to evaluate clinical activity of new anticancer drugs. Standardized criteria for evaluating response are needed for comparing results of different trials and represent the basis for advances in cancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 are the most used in clinical practice and in clinical trials; however, they are not able to capture atypical responses seen with immunotherapy drugs. We describe the evolution of response criteria with a special focus on the immune-related criteria.

Keywords

Immunotherapy irRC iRECIST irRECIST PERCIST RECIST

Get full access to this article

View all access options for this article.

References

Karnofsky

DA.

Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 1961; 2: 709–712.

Miller

Hoogstraten

Staquet

Winkler

Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

Therasse

Arbuck

Eisenhauer

et al . New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205–216.

Eisenhauer

Therasse

Bogaerts

et al . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

Antoch

Kanja

Bauer

et al . Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357–365.

Choi

Charnsangavej

de Castro Faria

et al . CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183: 1619–1628.

Choi

Charnsangavej

Faria

et al . Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753–1759.

Gavanier

Ayav

Sellal

et al . CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor [mRECIST]) versus RECIST 1.1. Eur J Radiol 2016; 85: 103–112.

Schmidt

Hess

Zumbrunn

Rothermundt

Bongartz

Potthast

Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 2013; 23: 632–639.

10.

Stacchiotti

Verderio

Messina

et al . Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 2012; 118: 5857–5866.

11.

Bruix

Sherman

Llovet

et al . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421–430.

12.

Lencioni

Llovet

JM.

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60.

13.

Bos

van Der Hoeven

van Der Wall

et al . Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20: 379–387.

14.

Wahl

Jacene

Kasamon

Lodge

MA.

From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl 1): 122S–150S.

15.

Emens

Ascierto

Darcy

et al . Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 2017; 81: 116–129.

16.

Wolchok

Hoos

O’Day

et al . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412–7420.

17.

Hoos

Eggermont

Janetzki

et al . Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102: 1388–1397.

18.

Chiou

Burotto

Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33: 3541–3543.

19.

Hodi

Hwu

Kefford

et al . Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34: 1510–1517.

20.

Nishino

Giobbie-Hurder

Gargano

Suda

Ramaiya

Hodi

FS.

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013; 19: 3936–3943.

21.

Bohnsack

Hoos

Ludajic

Adaptation of the immune-related response criteria: irRECIST. ESMO 2014. Abstract 4958.

22.

Eleneen

Colen

RR.

Cancer Imaging in Immunotherapy. Adv Exp Med Biol 2017; 995: 141–153.

23.

Le Lay

Jarraya

Lebellec

Penel

. IrRECIST and iRECIST: the devil is in the details. Ann Oncol 2017; 28: 1676–1678.

24.

Seymour

Bogaerts

Perrone

et al . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143–e152.

25.

Gandara

Von Pawel

Sullivan

et al . Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: results from the randomized phase III OAK study. J Clin Oncol 2017; 35 (suppl); abstract 9001.

26.

Inno

Metro

Bironzo

et al . Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori 2017; 103: 405–421.